The in vivo efficacy of the protein is also recently reported in a COVID-19 patient hospitalized in the Intensive Care Unit.27 We therefore believe that recombinant soluble ACE2 represents a promising drug candidate for COVID-19 treatment. This evidence concerns the gene ACE2 and COVID-19.